Pfizer, Schering-Plough, and Sanofi-Aventis in media crosshairs

The Motley Fool recently had criticism for Pfizer, which was recently named "one of the worst corporate evildoers for 2005" by a group called Global Exchange.   More troubling could be the potential for litigation involving Bextra. One suit has recently been filed. The negatives almost drowned out news of the positive work that Pfizer has been doing via the IFPMA, to reduce the costs of drugs for patients in developing countries.  The company has donated $1 billion in funds and medications to the effort, and Pfizer CEO Hank McKinnell will be the next president of that group. Various articles took a critical  look at Schering-Plough CEO Fred Hassan and the challenges that the company faces. The company is pursuing a "globalization" strategy. Could Sanofi-Aventis' Ambien, which has been, anecdotally connected with "sleepwalking, sleep-eating and other phenomena" be the next focus for pseudo-science and litigation? -AMS